US pharma giant Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have wasted no time following the announcement of positive preliminary Phase III data on their COVID-19.
They have announced that on Friday they will submit a request to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the USA by the middle to end of December.
"We now have a more complete picture of both the efficacy and safety profile of our vaccine"The submission is based on data including a vaccine efficacy rate of 95% demonstrated in the companies’ Phase III study in participants without prior SARS-CoV-2 infection, the trial’s first primary objective, and also in participants with and without prior SARS-CoV-2 infection in each case measured from seven days after the second dose.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze